skli
2021-07-17
Expected
Moderna Surges to Record High as Vaccine Maker Added to S&P 500<blockquote>随着疫苗制造商加入标普500，Moderna股价飙升至历史新高</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":179044650,"tweetId":"179044650","gmtCreate":1626478484770,"gmtModify":1631887912545,"author":{"id":3583042826015243,"idStr":"3583042826015243","authorId":3583042826015243,"authorIdStr":"3583042826015243","name":"skli","avatar":"https://static.tigerbbs.com/cb36785e9f320f479b566e1e20e9c3e3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Expected </p></body></html>","htmlText":"<html><head></head><body><p>Expected </p></body></html>","text":"Expected","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/179044650","repostId":1168174427,"repostType":4,"repost":{"id":"1168174427","kind":"news","pubTimestamp":1626445586,"share":"https://www.laohu8.com/m/news/1168174427?lang=zh_CN&edition=full","pubTime":"2021-07-16 22:26","market":"us","language":"en","title":"Moderna Surges to Record High as Vaccine Maker Added to S&P 500<blockquote>随着疫苗制造商加入标普500，Moderna股价飙升至历史新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1168174427","media":"Thestreet","summary":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped t","content":"<p>Moderna Inc. (<b>MRNA</b>) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.</p><p><blockquote>莫德纳公司（<b>MRNA</b>）在这家疫苗制造商预计将于下周进入标普500基准后，该公司股价周五飙升至历史新高。</blockquote></p><p> Moderna will replaceAlexion Pharmaceuticals (<b>ALXN</b>) in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (<b>AZN</b>) in December of last year.</p><p><blockquote>Moderna将取代Alexion制药公司（<b>ALXN</b>）在被英国阿斯利康(AstraZeneca)以390亿美元收购后，从7月21日星期三开盘开始，成为全球最受关注的指数（<b>AZN</b>）去年12月。</blockquote></p><p> Moderna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.</p><p><blockquote>Moderna股价周五早盘上涨6%，换手至每股275.92美元，创历史新高，这将使该股今年迄今的涨幅扩大至约165%，市值约为1110亿美元。</blockquote></p><p> Moderna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.</p><p><blockquote>Moderna 5月6日公布第一季度每股收益2.84美元，强于预期，营收增至19亿美元。该制药商还将2021财年全年疫苗销售额预测上调至约192亿美元。</blockquote></p><p> Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.</p><p><blockquote>Moderna 2021年的基本计划是生产8亿剂信使RNA疫苗，该疫苗于去年12月获得FDA的紧急批准，目标是“努力在2021年尽可能多地获得10亿剂疫苗”，Bancel在5月初表示。</blockquote></p><p> \"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"</p><p><blockquote>“世界各国政府要求高效mRNA疫苗和变异加强剂的反馈是压倒性的。我们现在正在积极与我们目前为2021年供应的所有政府进行2022年的讨论和协议。”</blockquote></p><p> Last month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.</p><p><blockquote>上个月，该组织正式请求美国食品和药物管理局紧急批准在未来几个月内向青少年接种其冠状病毒疫苗。</blockquote></p><p> Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.</p><p><blockquote>Moderna本周早些时候向欧洲卫生当局提出了类似的请求，该公司表示，其TeenCOVE研究的后期数据“达到了主要免疫原性终点，成功地将免疫反应与成人疫苗接种联系起来”，在2,500名参与者中，疫苗接种功效为100%。Moderna表示，在第一次接种两剂疫苗14天后，有效率也达到了93%。</blockquote></p><p> The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.</p><p><blockquote>该制药商要求FDA发布紧急使用授权(EUA)通知，允许其mRNA-1273用于12至18岁的儿童。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges to Record High as Vaccine Maker Added to S&P 500<blockquote>随着疫苗制造商加入标普500，Moderna股价飙升至历史新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges to Record High as Vaccine Maker Added to S&P 500<blockquote>随着疫苗制造商加入标普500，Moderna股价飙升至历史新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Thestreet</strong><span class=\"h-time small\">2021-07-16 22:26</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Moderna Inc. (<b>MRNA</b>) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.</p><p><blockquote>莫德纳公司（<b>MRNA</b>）在这家疫苗制造商预计将于下周进入标普500基准后，该公司股价周五飙升至历史新高。</blockquote></p><p> Moderna will replaceAlexion Pharmaceuticals (<b>ALXN</b>) in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (<b>AZN</b>) in December of last year.</p><p><blockquote>Moderna将取代Alexion制药公司（<b>ALXN</b>）在被英国阿斯利康(AstraZeneca)以390亿美元收购后，从7月21日星期三开盘开始，成为全球最受关注的指数（<b>AZN</b>）去年12月。</blockquote></p><p> Moderna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.</p><p><blockquote>Moderna股价周五早盘上涨6%，换手至每股275.92美元，创历史新高，这将使该股今年迄今的涨幅扩大至约165%，市值约为1110亿美元。</blockquote></p><p> Moderna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.</p><p><blockquote>Moderna 5月6日公布第一季度每股收益2.84美元，强于预期，营收增至19亿美元。该制药商还将2021财年全年疫苗销售额预测上调至约192亿美元。</blockquote></p><p> Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.</p><p><blockquote>Moderna 2021年的基本计划是生产8亿剂信使RNA疫苗，该疫苗于去年12月获得FDA的紧急批准，目标是“努力在2021年尽可能多地获得10亿剂疫苗”，Bancel在5月初表示。</blockquote></p><p> \"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"</p><p><blockquote>“世界各国政府要求高效mRNA疫苗和变异加强剂的反馈是压倒性的。我们现在正在积极与我们目前为2021年供应的所有政府进行2022年的讨论和协议。”</blockquote></p><p> Last month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.</p><p><blockquote>上个月，该组织正式请求美国食品和药物管理局紧急批准在未来几个月内向青少年接种其冠状病毒疫苗。</blockquote></p><p> Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.</p><p><blockquote>Moderna本周早些时候向欧洲卫生当局提出了类似的请求，该公司表示，其TeenCOVE研究的后期数据“达到了主要免疫原性终点，成功地将免疫反应与成人疫苗接种联系起来”，在2,500名参与者中，疫苗接种功效为100%。Moderna表示，在第一次接种两剂疫苗14天后，有效率也达到了93%。</blockquote></p><p> The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.</p><p><blockquote>该制药商要求FDA发布紧急使用授权(EUA)通知，允许其mRNA-1273用于12至18岁的儿童。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500\">Thestreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","ALXN":"亚力兄制药","MRNA":"Moderna, Inc."},"source_url":"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168174427","content_text":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN) in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.\nModerna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.\nModerna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.\nModerna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.\n\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"\nLast month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.\nModerna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.\nThe drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.","news_type":1,"symbols_score_info":{"AZN":0.9,"ALXN":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1752,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/179044650"}
精彩评论